Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566

This publication has 11 references indexed in Scilit:

• Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer
  Diseases of the Colon & Rectum, 2000
• Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies
  Journal of Clinical Oncology, 2000
• Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer
  Diseases of the Colon & Rectum, 1999
• QUANTITATIVE HPLC ANALYSIS OF 4-[4-4-(CHLOROPHENYL)PHENYL]-4-OXO-2S-(PHENYLTHIOMETHYL) BUTANOIC ACID (BAY 12-9566), A METALLOPROTEINASE INHIBITOR, AND ITS METABOLITES IN HUMAN PLASMA
  Journal of Liquid Chromatography & Related Technologies, 1999
• Changing views of the role of matrix metalloproteinases in metastasis
  JNCI Journal of the National Cancer Institute, 1997
• Matrix Metalloproteinase Inhibitor Drugs
  Emerging Drugs, 1997
• Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
  Proceedings of the National Academy of Sciences, 1997
• Matrix metalloproteinase inhibition: A review of anti-tumour activity
  Annals of Oncology, 1995
• Matrix Metalloproteinases and Their Inhibitors in Tumor Progression^a
  Annals of the New York Academy of Sciences, 1994
• Regulation of Matrix Metalloproteinase Activity^a
  Annals of the New York Academy of Sciences, 1994